Impax Labs Inc patent expiration

1. Rytary patent expiration

RYTARY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7094427 IMPAX LABS INC Combination immediate release controlled release levodopa/carbidopa dosage forms
May, 2022

(2 years ago)

US9901640 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9089607 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8454998 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8377474 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US8557283 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9463246 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9533046 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)

US9089608 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 07, 2018

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 07 January, 2015

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Method of p...

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of RYTARY before it's drug patent expiration?
More Information on Dosage

RYTARY family patents

Family Patents